A Multi-center, Randomized Clinical Trial of Chidamide Combined With Azacytidine and the HAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Patients

The First Affiliated Hospital of Soochow University1 个研究点分布在 1 个国家目标入组 21 人开始时间: 2021年9月1日最近更新: 2026年3月19日

适应症

干预措施

试验速览

阶段: 2 期
状态: 进行中（未招募）
发起方
入组人数: 21
试验地点: 1
主要终点: Complete remission without minimal residual disease (CR with MRD-)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study is to investigate the therapeutic efficacy and side effect of chidamide, azacitidine combined with priming HAG regimen for relapsed or refractroy acute myeloid leukemia

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 69 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Adults aged ≥ 18 and ≤ 70 years
•Patients diagnosed with AML according to 2016 WHO myeloid malignant disease diagnosis standard (Non-APL)
•Patients with AML must meet one of the following criteria, A or B:
•A: Refractory AML disease was defined as follows: (1) failure to attain CR following exposure to at least 2 courses of standard or intensive induction therapy; or (2) bone marrow leukemia cell decline index (BMCDI) < 50% and > 20% after 1 course of standard or intensive induction therapy. B: Relapsed AML disease was defined as follows: (1) reappearance of leukemic blasts in the peripheral blood after CR; or (2) detection of ≥ 5% blasts in the BM not attributable to another cause (e.g., BM regeneration after consolidation therapy); or (3) extramedullary relapse.
•ECOG performance status score less than 3
•Expected survival time ˃ 3 months
•Patients without serious heart, lung, liver, or kidney disease
•Ability to understand and voluntarily provide informed consent

排除标准

•Patients who are allergic to the study drug or drugs with similar chemical structures
•Pregnant or lactating women, and women of childbearing age who do not want to practice effective methods of contraception
•Active infection
•Active bleeding
•Patients with new thrombosis, embolism, cerebral hemorrhage, or other diseases or a medical history within one year before enrollment
•Patients with mental disorders or other conditions whereby informed consent cannot be obtained and where the requirements of the study treatment and procedures cannot be met
•Liver function abnormalities (total bilirubin > 1.5 times the upper limit of the normal range, ALT/AST > 2.5 times the upper limit of the normal range or patients with liver involvement whose ALT/AST > 1.5 times the upper limit of the normal range), or renal anomalies (serum creatinine > 1.5 times the upper limit of the normal value)
•Patients with a history of clinically significant QTc interval prolongation (male > 450 ms; female > 470 ms), ventricular heart tachycardia and atrial fibrillation, II-degree heart block, myocardial infarction attack within one year before enrollment, and congestive heart failure, and patients with coronary heart disease who have clinical symptoms and requiring drug treatment
•Surgery on the main organs within the past six weeks
•Drug abuse or long-term alcohol abuse that would affect the evaluation results
•Patients who have received organ transplants (excepting bone marrow transplantation)
•Patients not suitable for the study according to the investigator's assessment

研究组 & 干预措施

Chidamide+AZA+HHT+AraC+G-CSF group

Experimental

The patients are randomized into the group. Patients whose last induction failure regimen is a demethylated agent combined with priming regimen enter the experimental group directly.

干预措施: CAHAG regimen (Drug)

Placebo+AZA+HHT+AraC+G-CSF group

Placebo Comparator

The patients are randomized into the group.

干预措施: Placebo regimen (Drug)